ProPhase LabsPRPH -2.50% 10-Year RORE % is 334.52 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 99.17% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
ProPhase Labs's 10-Year RORE % for the quarter that ended in Mar. 2026 was 334.52%.
The industry rank for ProPhase Labs's 10-Year RORE % or its related term are showing as below:
PRPH's 10-Year RORE % is ranked better than 99.17% of 121
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.83
vs PRPH: 334.52
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
ProPhase Labs 10-Year RORE % Related Terms
ProPhase Labs 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, IVRO, FUNI: 10-Year RORE % Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs 10-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
ProPhase Labs (PRPH) has a 10-Year RORE % of 334.52 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #1 out of 121 companies in the Medical Diagnostics & Research industry, placing it in the top 0.8%.
Is ProPhase Labs' 10-Year RORE % too high?
ProPhase Labs' current 10-Year RORE % is 334.52. The Medical Diagnostics & Research industry median 10-Year RORE % is 0.83. ProPhase Labs' value of 334.52 is 40203.6% above this industry median. Based on the distribution chart, ProPhase Labs ranks #1 out of 121 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ProPhase Labs' 10-Year RORE % compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #1 out of 121 companies for 10-Year RORE %. This places ProPhase Labs in the top 1% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 0.83. ProPhase Labs' value of 334.52 is 40203.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
The median 10-Year RORE % among Medical Diagnostics & Research companies is 0.83, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current 10-Year RORE % of 334.52 is 40203.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year RORE % is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current 10-Year RORE % is 334.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.85, compared to a current price of $0.08 — trading 90.8% below its estimated fair value. The current 10-Year RORE % is 334.52 and 40203.6% above the Medical Diagnostics & Research industry median of 0.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current 10-Year RORE % is 334.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 